Edition:
United States

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

3.71USD
18 Jan 2019
Change (% chg)

$-0.09 (-2.37%)
Prev Close
$3.80
Open
$3.82
Day's High
$3.90
Day's Low
$3.64
Volume
22,181
Avg. Vol
36,954
52-wk High
$23.67
52-wk Low
$3.39

Latest Key Developments (Source: Significant Developments)

Mersana Therapeutics Says XMT-1522 Development Discontinued Following Strategic Evaluation
Friday, 4 Jan 2019 07:00am EST 

Jan 4 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES STRATEGIC PRIORITIES AND GOALS FOR 2019 AND BEYOND.MERSANA THERAPEUTICS INC - XMT-1522 DEVELOPMENT DISCONTINUED FOLLOWING STRATEGIC EVALUATION.MERSANA THERAPEUTICS INC - DOSE SELECTION AND INITIATION OF XMT-1536 EXPANSION COHORTS ON TRACK FOR FIRST HALF 2019.MERSANA THERAPEUTICS - TO FOCUS RESOURCES ON ADVANCING XMT-1536, ITS FIRST-IN-CLASS ADC CANDIDATE TARGETING NAPI2B, SHOWING ENCOURAGING EARLY SIGNS OF EFFICACY.MERSANA THERAPEUTICS - FOR XMT-1536, EXPECTS TO SELECT DOSE FOR USE IN PHASE 1 EXPANSION STUDIES, INITIATE ENROLLMENT OF PATIENTS IN EXPANSION COHORTS IN H1 2019.MERSANA THERAPEUTICS INC - EXPECTS TO DISCLOSE ITS NEXT CLINICAL CANDIDATE IN SECOND HALF OF 2019.MERSANA THERAPEUTICS INC - MERSANA AND ITS PARTNER, TAKEDA, PLAN TO TERMINATE CO-DEVELOPMENT COLLABORATION FOR XMT-1522.MERSANA THERAPEUTICS INC - TARGETING FILING OF IND APPLICATION WITH FDA IN FIRST HALF OF 2020.MERSANA THERAPEUTICS INC - PROACTIVELY EVALUATING POTENTIAL FOR STRATEGIC COLLABORATIONS.  Full Article

Mersana Appoints David Spellman As Chief Financial Officer
Monday, 12 Mar 2018 08:00am EDT 

March 12 (Reuters) - Mersana Therapeutics Inc ::MERSANA APPOINTS DAVID A. SPELLMAN AS CHIEF FINANCIAL OFFICER.MERSANA THERAPEUTICS INC - SPELLMAN JOINS MERSANA FROM VERTEX.  Full Article

Mersana announces third quarter loss of $0.35 per share
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Mersana Therapeutics Inc :Mersana announces third quarter 2017 financial results and provides business updates.Qtrly ‍loss per share $0.35​.Cash, cash equivalents and marketable securities as of Sept 30, 2017 were $133.4 million, compared with $100.3 million as of Dec 31, 2016​.Expects that cash, cash equivalents and marketable securities will enable it to fund operating plan through at least mid-2019​.  Full Article

Mersana announces FDA clearance of IND application for XMT-1536
Monday, 30 Oct 2017 07:30am EDT 

Oct 30 (Reuters) - Mersana Therapeutics Inc :Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b.‍U.S. FDA cleared company's investigational new drug application to begin phase 1 clinical trials for XMT-1536​.  Full Article

Mersana Q2 loss per share $6.33
Friday, 11 Aug 2017 07:00am EDT 

Aug 11 (Reuters) - Mersana Therapeutics Inc :Mersana announces second quarter 2017 financial results and provides business updates.Q2 loss per share $6.33.Q2 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.Mersana therapeutics - ‍expects cash, cash equivalents and marketable securities will enable it to fund its operating plan through at least mid-2019..Mersana therapeutics - ‍cash, cash equivalents and marketable securities as of june 30, were $77.2 million, compared with $100.3 million as of december 31, 2016​.Mersana therapeutics inc - qtrly ‍collaboration revenue $3.7 million versus $6.2 million​.Q2 earnings per share view $-0.69, revenue view $3.9 million -- Thomson Reuters I/B/E/S.  Full Article

Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017
Friday, 7 Jul 2017 04:41pm EDT 

July 7 (Reuters) - Rock Springs Capital Management LP: :Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing.  Full Article

Mersana Therapeutics sees IPO of 5 mln shares priced between $14 and $16
Friday, 16 Jun 2017 06:07am EDT 

June 16 (Reuters) - Mersana Therapeutics Inc ::Mersana Therapeutics Inc sees IPO of 5 million shares priced between between $14.00 and $16.00 - SEC filing.  Full Article

Mersana's cancer drug trial put on hold by FDA; shares halted

Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after a patient's death was possibly linked to the treatment.